BHP SAYS INJECTABLE CABOTEGRAVIR IS MORE EFFECTIVE THAN TRUVADA IN HIV PREVENTION
Written by admin on December 4, 2020
As the world celebrates world AIDS day in muted tones due to the COVID19 pandemic this year, Botswana continues to make great strides in the disease management.
The Botswana Harvard Aids Institute Partnership, BHP, says their latest HIV prevention trials, which compared the safety and efficacy of injectable cabo-tegravir with oral TRUVADA, have revealed that injectable cabotegravir is more effective in HIV prevention. The Coordinator of the study Dr. Alice Sehurutshi says 1 percent of paricipants in the study contracted HIV, which indicated that the injectable cabotegravir was more superior than the TRUVADA. She said the study was done in 20 countries including Botswana, with over 90 high risk participates recruited since late 2017 in the country. She said some of the participants were given oral Truvada, while others were injected with cabotegravir, and results showed that the injection was more effective in HIV prevention than TRUVADA.